Showing results (171-180 of 183) with videos related to
Sort By:
Pageof 19
Hepatology (Baltimore, Md.)|December 9, 2017
Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural historyCarla F Murillo Perez, Jorn C Goet, Willem J Lammers, et al.Journal of Translational Medicine|April 5, 2025
Tobacco smoke exposure is a driver of altered oxidative stress response and immunity in head and neck cancerYang Li, Pedram Yadollahi, Fonma N Essien, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 8, 2019
Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary CholangitisAngela C Cheung, Willem J Lammers, Carla F Murillo Perez, et al.European Journal of Gastroenterology & Hepatology|December 5, 2022
Geographical region and clinical outcomes of patients with primary biliary cholangitis from Western EuropeCarla F Murillo Perez, Alessio Gerussi, Palak J Trivedi, et al.The American Journal of Gastroenterology|July 4, 2020
Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline PhosphataseCarla F Murillo Perez, Maren H Harms, Keith D Lindor, et al.Liver International : Official Journal of the International Association for the Study of the Liver|May 9, 2023
Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one-year non-responders and predicts survivalC Fiorella Murillo Perez, Stephanie Ioannou, Iman Hassanally, et al.Journal of Hepatology|May 10, 2023
Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting reportRaúl J Andrade, Guruprasad P Aithal, Ynto S de Boer, et al.Journal of Hepatology|May 11, 2025
Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trialCynthia Levy, George F Abouda, Bahri M Bilir, et al.Gastroenterology|September 23, 2022
Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External ControlsC Fiorella Murillo Perez, Holly Fisher, Shaun Hiu, et al.Hepatology (Baltimore, Md.)|June 30, 2023
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled studyGideon M Hirschfield, Mitchell L Shiffman, Aliya Gulamhusein, et al.Pageof 19